Table 1 Cohort characteristics.
Characteristic | Entire Cohort (n = 1487) | Sub-cohort (n = 309) |
|---|---|---|
Age, mean (SD), y | 64.7 (10.1) | 63.1 (10.1) |
Sex | ||
Male | 703 (47.3%) | 149 (48.2%) |
Female | 784 (52.7%) | 160 (51.8%) |
Race and ethnicity | ||
Asian | 93 (6.3%) | 20 (6.5%) |
Black | 150 (10.1%) | 38 (12.3%) |
White | 835 (56.1%) | 176 (57.0%) |
Other | 44 (3.0%) | 11 (3.5%) |
Unknown | 365 (24.5%) | 64 (20.7%) |
Primary Tumor Histology | ||
Adenocarcinoma | 1078 (72.5%) | 233 (75.4%) |
Squamous | 267 (18.0%) | 50 (16.2%) |
Other/Not Specified | 142 (9.5%) | 26 (8.4%) |
Initial Reported Stage | ||
Not Reported | 51 (3.4%) | 1 (0.3%) |
Stage 0 | 1 (0.1%) | 0 (0.0%) |
Stage I | 87 (5.8%) | 9 (2.9%) |
Stage II | 70 (4.7%) | 4 (1.3%) |
Stage III | 272 (18.3%) | 34 (11.0%) |
Stage IV | 1006 (67.7%) | 261 (84.5%) |
Driver Gene Alterations (Pre-Liquid Biopsy) | ||
EGFR | 251 (16.9%) | 53 (17.2%) |
ALK | 50 (3.4%) | 9 (2.9%) |
ROS1 | 21 (1.4%) | 2 (0.6%) |
MET | 25 (1.7%) | 8 (2.6%) |
RET | 7 (0.5%) | 1 (0.3%) |
BRAF | 36 (2.4%) | 9 (2.9%) |
KRAS | 72 (4.8%) | 16 (5.2%) |
ERBB2 | 14 (0.9%) | 3 (1.0%) |
Metastatic organ systems, meana (SD, range) | 1.3 (0.64, 1–8) | 1.3 (0.56, 1–5) |
PD-L1 Statusb | ||
Positive | 302 (20.3%) | 59 (19.1%) |
Negative | 202 (13.6%) | 48 (15.5%) |
Unknown | 983 (66.1%) | 202 (65.4%) |
Smoking Status | ||
Current/Former Smoker | 1006 (67.7%) | 221 (71.5%) |
Never Smoker | 323 (21.7%) | 73 (23.6%) |
Unknown | 158 (10.6%) | 15 (4.9%) |
Documented Radiotherapy | 975 (66%) | 309 (100%) |
Reported Lines of Therapy | ||
Not Reported | 212 (14.3%) | 34 (11.0%) |
1 | 674 (45.3%) | 128 (41.4%) |
2 | 374 (25.1%) | 93 (30.1%) |
3 | 141 (9.5%) | 33 (10.7%) |
≥4 | 86 (5.8%) | 21 (6.8%) |
